Researchers have identified a potential strategy to intervene earlier in pancreatic cancer by targeting the FGFR2 gene alongside EGFR. This “interception” approach aims to stop the disease before it becomes aggressive. Pancreatic cancer is currently the third leading cause of cancer-related death in the United States and is projected to rise to second by 2030.
Early detection remains a major challenge. The pancreas is deep in the body and early symptoms are often subtle, so most patients are diagnosed at advanced stages. Overall, the five-year survival rate is about 13%. If diagnosed early and localized, survival improves to around 44%, but only about 15% of cases are caught at this stage. Survival drops sharply with disease spread, to roughly 16% for regional spread and 3% for distant metastasis.
Racial and ethnic disparities are significant. Black or African American individuals have the highest incidence and mortality and the lowest five-year survival, around 11%. Other groups, including White, Hispanic, and Asian or Pacific Islander patients, generally have survival rates of 12% to 14%. These differences are linked to later diagnosis, reduced access to specialized care, and possibly biological factors. By 2030, annual U.S. deaths are expected to reach 63,000. The interception approach offers hope that earlier, targeted treatment—especially for high-risk populations—could improve outcomes and help reduce disparities.